Cost considerations of therapeutic options for children with asthma

Pediatric Drugs

Volumn 14, Issue 4, 2012, Pages 211-220

  Chuang, Sandra ^a   Jaffe, Adam ^a,b  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Asthma; Children; Corticosteroids; Cost effectiveness; Economic implications; Healthcare expenditure; Inhaler devices.

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CICLESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; MONTELUKAST; SALMETEROL;

ARTICLE; ASTHMA; CHILD; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MEGADOSE; HEALTH CARE COST; HUMAN; LOW DRUG DOSE; METERED DOSE INHALER; PRESCRIPTION; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INAPPROPRIATE PRESCRIBING; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC;

EID: 84862532274     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11597360-000000000-00000     Document Type: Article

References (69)

1. Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004 May 59 (5): 469-478
2. Australian Centre for Asthma Monitoring. Asthma in Australia 2008. Canberra (ACT): Australian Institute of Health and Welfare, 2008 [online] Available from URL: http://www.aihw.gov.au/search/?q=asthma+in+ australia+2008 [Accessed 2012 Apr 2]
3. Lai CK, Beasley R, Crane J, et al. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2009 Jun 64 (6): 476-483
4. Australian Centre for Asthma Monitoring. Asthma in Australian children: findings from Growing Up in Australia, the Longitudinal Study of Australian Children. Canberra (ACT): Australian Institute of Health and Welfare, 2009 [online]. Available from URL: http://www.aihw.gov.au/publication-detail/ ?id=6442468289&tab=2 [Accessed 2012 Apr 2]
5. Braman S. The global burden of asthma. Chest 2006 130 (1 Suppl.): 4-12S
6. Australian Centre for Asthma Monitoring. Health care expenditure and the burden of disease due to asthma in Australia [online]. Available from URL: www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=6442453732 [Accessed 2012 Apr 18]
7. Australian Centre for Asthma Monitoring. Burden of disease due to asthma in Australia 2003. Canberra (ACT): Australian Institute of Health and Welfare, 2009 [online]. Available from URL: http://www.aihw.gov.au/publicationdetail/? id=6442468278 [Accessed 2012 Apr 18]
8. Global Initiative for Asthma. Global strategy for asthma management and prevention 2010 [online]. Available from URL: www.ginasthma.org/pdf/ GINA-Report-2010.pdf [Accessed 2012 Apr 18]
9. Mintzes B, Barer ML, Kravitz RL, et al. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. CMAJ 2003 Sep 2 169 (5): 405-412
10. Pharmaceutical Health and Rational Use of Medicines Committee. Direct to consumer advertising (DTCA) or prescription medicines and the quality use of medicines (QUM) 2004 [online]: Available from URL: http://www.health. gov.au/internet/main/publishing.nsf/Content/43A536BA7ABC1DA5CA256 F9D00168F17/File/dtca.pdf [Accessed 2012 Apr 2]
11. Mintzes B, Barer ML, Kravitz RL, et al. Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. BMJ 2002 Feb 2 324 (7332): 278-279
12. Vitry A. Is Australia free from direct-to-consumer advertising? Aust Prescrib 2004 27 (1): 4-6
13. Mintzes B. An assessment of the health system impacts of direct-to-consumer advertising of prescription medicines. Vol. 2. Literature review. Vancouver (BC): University of British Columbia, 2001
14. Mintzes B. Direct-to-consumer prescription drug advertising. The European Commission's proposals for legislative change. Health Action International (HAI-Europe), December 2001 [online]. Available from URL: www.haiweb. org/campaign/DTCA/BMintzes-en.pdf [Accessed 2012 Apr 2]
15. Australian Marketing Institute. Australian Marketing Institute awards 2002 [online]. Available from URL: http://www.ami.org.au/librarymanager/libs/ 31/2002-winners.pdf
16. British Thoracic Society. British Guideline on the Management of Asthma 2009 [online]: Available from URL: http://www.brit-thoracic.org.uk/Clin icalInformation/Asthma/AsthmaGuidelines/tabid/83/Default.aspx [Accessed 2012 Apr 2]
17. Global Initiative for Asthma. Pocket guide for asthma management and prevention in 5 years and younger [online]: Available from URL: http://www. ginasthma.org/guidelines-pocket-guide-for-Asthma-management-And-preventionin. html [Accessed 2012 Apr 18]
18. National Asthma Education and Prevention Program Coordinating Committee. Expert panel report 3 (EPR3): guidelines for the diagnosis and management of asthma [online]: Available from URL: http://www.nhlbi.nih.gov/ guidelines/asthma/asthgdln.htm [Accessed 2012 Apr 2]
19. National Asthma Council Australia. Asthma management handbook 2006. South Melbourne (VIC): National Asthma Council Australia Ltd, 2006 [online]. Available from URL: http://www.nationalasthma.org.au/content/ view/252/591/ [Accessed 2012 Apr 2]
20. Australian Institute of Health and Welfare. General practice in Australia, health priorities and policies 1998-2008 (General Practice Series No. 24) [online]. Available from URL: http://www.aihw.gov.au/publication-detail/ ?id=6442468257&tab=2 [Accessed 2012 Apr 2]
21. Australian Institute of Health and Welfare, GP Statistics and Classification Centre. SAND abstract no. 129 from the BEACH program 2008-09: Asthma in general practice patients [online]. Available from URL: http://sydney. edu.au/medicine/fmrc/publications/sand-Abstracts/129-Asthma.pdf [Accessed 2012 Apr 2]
22. Phillips CB, Toyne H, Ciszek K, et al. Trends in medication use for asthma in school-entry children in the Australian Capital Territory, 2000-2005. Med J Aust 2007 Jul 2 187 (1): 10-13
23. Johansson M, Hall J, Reith J, et al. Trends in the use of inhaled corticosteroids for childhood asthma in New Zealand. Eur J Clin Pharmacol 2003 59: 483-487
24. Turner S, Thomas M, von Ziegenweidt J, et al. Prescribing trends in asthma: A longitudinal observational study. Arch Dis Child 2008 94: 16-22
25. Brown M, Phillips CB, Ciszek K, et al. Children in the ACT with asthma: Are they taking preventer medication according to guidelines? Aust Fam Physician 2010 Mar 39 (3): 146-149
26. Paton J, Jardine E, McNeill E, et al. Adrenal responses to low dose synthetic ACTH (Synacthen) in children receiving high dose inhaled fluticasone. Arch Dis Child 2006 Oct 91 (10): 808-813
27. Gulliver T, Morton R, Eid N. Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical consiDerations. Paediatr Drugs 2007 9 (3): 185-194
28. Hancox RJ, Le Souef PN, AnDerson GP, et al. Asthma: time to confront some inconvenient truths. Respirology 2010 Feb 15 (2): 194-201
29. Janson C, de Marco R, Accordini S, et al. Changes in the use of antiasthmatic medication in an international cohort. Eur Respir J 2005 26: 1047-1055
30. Australian Centre for Asthma Monitoring. Patterns of asthma medication use in Australia 2007 [online]. Available from URL: http://www.aihw.gov.au/ publication-detail/?id=6442467976 [Accessed 2012 Apr 2]
31. PeDersen S. From asthma severity to control: A shift in clinical practice. Prim Care Respir J 2010 Mar 19 (1): 3-9
32. Yawn BP, Brenneman SK, Allen-Ramey FC, et al. Assessment of asthma severity and asthma control in children. Pediatrics 2006 Jul 118 (1): 322-329
33. Cohen S, Taitz J, Jaffe A. Paediatric prescribing of asthma drugs in the UK: Are we sticking to the guideline? Arch Dis Child 2007 Oct 92 (10): 847-849
34. Adverse Drug Reactions Advisory Committee. Corticosteroids should be used with long acting B2 agonists. Aust Adv Drug React Bull 2004 23 (3) [online]. Available from URL: http://www.tga.gov.au/hp/aadrb-0406.htm [Accessed 2012 Apr 18]
35. de Vries TW, Tobi H, Schirm E, et al. The gap between evidence-based medicine and daily practice in the management of paediatric asthma: A pharmacybased population study from The Netherlands. Eur J Clin Pharmacol 2006 62: 51-55
36. Ko FW, Chan AM, Chan HS, et al. Are Hong Kong doctors following the Global Initiative for Asthma guidelines: A questionnaire ''Survey on Asthma Management''? Hong Kong Med J 2010 Apr 16 (2): 86-93, quiz 5 p following 893
37. Friedman HS, Eid NS, Crespi S, et al. Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations. Clin Ther 2009 May 31 (5): 1056-1063
38. US Food and Drug Administration. Information for Healthcare Professionals: salmeterol xinafoate [marketed as Serevent Diskus] 2010 [online]: Available from URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrug SafetyInformationforPatientsandProviDers/ucm162673.htm [Accessed 2012 Apr 2]
39. Elkout H, Helms PJ, Simpson CR, et al. Changes in primary care prescribing patterns for paediatric asthma: A prescribing database analysis. Arch Dis Child. Epub 2011 May 19
40. Breton MC, Lelorier J, Forget A, et al. Use of combination therapy in asthma: Are they prescribed according to guidelines. Respir Med 2007 101 (9): 1916-1923
41. Thomas M, Murray-Thomas T, Fan T, et al. Prescribing patterns of asthma controller therapy for children in UK primary care: A cross-sectional observational study. BMC Pulm Med 2010 10: 29
42. Ni Chroinin M, Greenstone I, Lasserson TJ, et al. Addition of inhaled longacting beta2-Agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev 2009 (4): CD005307
43. Tan C, Wong B, Goh DY, et al. Monitoring and treatment practices of childhood asthma in Singapore: A questionnaire study. Singapore Med J 2009 Jan 50 (1): 54-61
44. Neville RG, Hoskins G, Smith B, et al.How general practitioners manage acute asthma attacks. Thorax 1997 Feb 52 (2): 153-156
45. Gibson PG, Wilson AJ. The use of continuous quality improvement methods to implement practice guidelines in asthma. J Qual Clin Pract 1996 Jun 16 (2): 87-102
46. Anis AH, Lynd LD, Wang XH, et al. Double trouble: impact of inappropriate use of asthma medication on the use of health care resources. CMAJ2001 Mar 6 164 (5): 625-631
47. Neville RG, Hoskins G, Smith B, et al. Observations on the structure, process and clinical outcomes of asthma care in general practice. Br J Gen Pract 1996 Oct 46 (411): 583-587
48. Legorreta AP, Christian-Herman J, O'Connor RD, et al. Compliance with national asthma management guidelines and specialty care. Arch Intern Med 1998 158: 457-464
49. Cloutier MM, Hall CB, Wakefield DB, et al. Use of asthma guidelines by primary care proviDers to reduce hospitalizations and emergency department visits in poor, minority, urban children. J Pediatr 2005 May 146 (5): 591-597
50. Cabana MD, Ebel BE, Cooper-Patrick L, et al. Barriers pediatricians face when using asthma practice guidelines. Arch Pediatr Adolesc Med 2000 Jul 154 (7): 685-693
51. Price D, Thomas M. Breaking new ground: challenging existing asthma guidelines. BMC Pulm Med 2006 6 Suppl. 1: S6
52. Hernandez DV, Schmaling KB. UnDerstanding and resolving adherence problems. Clin Rev Allergy Immunol 2004 Oct 27 (2): 65-73
53. Reed CE. Inhaled corticosteroids: why do physicians and patients fail to comply with guidelines for managing asthma? Mayo Clin Proc 2004 Apr 79 (4): 453-455
54. Lang DM, Sherman MS, Polansky M. Guidelines and realities of asthma management: the Philadelphia story. Arch Intern Med 1997 Jun 9 157 (11): 1193-1200
55. Main C, Shepherd J, AnDerson R, et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-Acting beta2 agonists for the treatment of chronic asthma in children unDer the age of 12 years. Health Technol Assess 2008 May 12 (20): 1-174, iii-iv
56. Shepherd J, Rogers G, AnDerson R, et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-Acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over. Health Technol Assess 2008 May 12 (19): iii-iv, 1-360
57. Ni Chroinin M, Lasserson TJ, Greenstone I, et al. Addition of long-Acting betaagonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev 2009 (3): CD007949
58. Lasserson TJ, Cates CJ, Ferrara G, et al. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database Syst Rev 2008 (3): CD004106
59. de Blic J, Ogorodova L, Klink R, et al. Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children. Pediatr Allergy Immunol 2009 Dec 20 (8): 763-771
60. Gappa M, Zachgo W, von Berg A, et al. Add-on salmeterol compared to double dose fluticasone in pediatric asthma: A double-blind, randomized trial (VIAPAED). Pediatr Pulmonol 2009 Nov 44 (11): 1132-1142
61. Vaessen-Verberne AA, Van den Berg NJ, Van Nierop JC, et al. Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. Am J Respir Crit Care Med 2010 Nov 15 182 (10): 1221-7
62. Lemanske Jr RF, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. Mar 18 362 (11): 975-985
63. Bisgaard H. Effect of long-Acting beta2 agonists on exacerbation rates of asthma in children. Pediatr Pulmonol 2003 Nov 36 (5): 391-398
64. Van Asperen PP, Mellis CM, Sly PD, et al. The role of corticosteroids in the management of childhood asthma [online]. Available from URL: http:/ www.thoracic.org.au/imagesDB/wysiwyg/Steroidsinasthma-2010.pdf [Accessed 2012 Apr 2]
65. Price D, Wiren A, Kuna P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy 2007 Oct 62 (10): 1189-1198
66. Johansson G, Andreasson EB, Larsson PE, et al. Cost effectiveness of budesonide/ formoterol for maintenance and reliever therapy versus salmeterol/ fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics 2006 24 (7): 695-708
67. Wickstrom J, Dam N, Malmberg I, et al. Cost-effectiveness of budesonide/ formoterol for maintenance and reliever asthma therapy in Denmark: costeffectiveness analysis based on five randomised controlled trials. Clin Respir J 2009 Jul 3 (3): 169-180
68. Louis R, Joos G, Michils A, et al. A comparison of budesonide/formoterol maintenance and reliever therapy vs. conventional best practice in asthma management. Int J Clin Pract 2009 Oct 63 (10): 1479-1488
69. Bisgaard H, Le Roux P, Bjamer D, et al. Budesonide/formoterol maintenance plus reliever therapy: A new strategy in pediatric asthma. Chest 2006 Dec 130 (6): 1733-1743